血小板受体作为抗血小板治疗靶点的研究进展

舒雪梅; 郭涛

doi:10.13201/j.issn.1004-2806.2020.01.004

血小板受体作为抗血小板治疗靶点的研究进展

舒雪梅,
郭涛^,

- 华中科技大学同济医学院附属协和医院血液科(武汉, 430022)
基金项目:
国家自然科学基金项目(No:81974008)

详细信息

通讯作者: 郭涛,华中科技大学同济医学院附属协和医院血液科主任医师、博士生导师。担任中国医师协会血液科医师分会委员、中华血液学会血栓与止血学组委员、武汉市血液学会主任委员,中国研究型医院协会生物治疗学组常务委员。《临床血液学杂志》,《血栓与止血学杂志》,《国际输血及血液学杂志》及《临床急诊杂志》编委。E-mail:guotao1968@163.com

中图分类号: R558

收稿日期: 2019-11-18

Research progress of platelet receptor as antiplatelet therapeutic target

SHU Xuemei,
GUO Tao^,

More Information

Corresponding author: GUO Tao, E-mail: guotao1968@163.com

Received Date: 18 November 2019

摘要

摘要: 血小板在血栓形成过程中发挥着重要的作用。作用于血小板黏附,聚集等过程的抗血小板药物能有效地抑制体内血栓形成,预防和治疗急性冠脉综合征和缺血性脑卒中,抑制动脉粥样斑块破裂后的血栓形成,预防支架血栓形成。抗血小板治疗的作用靶点很多,本文主要对血小板上二磷酸腺苷受体,蛋白激酶受体,膜糖蛋白受体,血栓烷A2受体等受体及其拮抗剂的临床研究进展进行综述。1 血小板的功能及血小板膜受体的类型血小板的黏附、聚集、释放在动脉内血栓形成的过程中发挥
- 抗血小板药物 /
- 血小板受体
- antiplatelet agents /
- platelet receptors

HTML全文

参考文献(33)

[1]	Yun SH,Sim EH,Goh RY,et al.Platelet Activation:The Mechanisms and Potential Biomarkers[J].Biomed Res Int,2016,2016:9060143.
[2]	Koupenova M,Kehrel BE,Corkrey HA,et al.Thrombosis and platelets:an update[J].Eur Heart J,2017,38:785-791.
[3]	Andre P.Intracellular signaling as a potential target for antiplatelet therapy[J].Handb Exp Pharmacol,2012,210:339-367.
[4]	Fanaroff AC,Hasselblad V,Roe MT,et al.Antithrombotic agents for secondary prevention after acute coronary syndromes:A systematic review and network meta-analysis[J].Int J Cardiol,2017,241:87-96.
[5]	Ford NF.The Metabolism of Clopidogrel:CYP2C19 Is a Minor Pathway[J].J Clin Pharmacol,2016,56:1474-1483.
[6]	Ray S.Clopidogrel resistance:the way forward[J].Indian Heart J,2014,66:530-534.
[7]	Yuan S,Chan HCS,Vogel H,et al.The Molecular Mechanism of P2Y1 Receptor Activation[J].Angew Chem Int Ed Engl,2016,55:10331-10335.
[8]	Zhang D,Gao Z,Zhang K,et al.Two disparate ligand-binding sites in the human P2Y1 receptor[J].Nature,2015,520:317-321.
[9]	Cattaneo M.P2Y12 receptors:structure and function[J].J Thromb Haemost,2015,13:S10-S16.
[10]	Yusuf S,Zhao F,Mehta SR,et al.Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation[J].N Engl J Med,2001,345:494-502.
[11]	Michelson AD.Antiplatelet therapies for the treatment of cardiovascular disease[J].Nat Rev Drug Discov,2010,9:154-169.
[12]	Adamski P,Buszko K,Sikora J,et al.Metabolism of ticagrelor in patients with acute coronary syndromes[J].Sci Rep,2018,8:11746.
[13]	Mehta SR.Cangrelor:a new CHAMPION for percutaneous coronary intervention[J].Lancet,2013,382:1960-1962.
[14]	Schneider DJ.Anti-platelet therapy:glycoprotein Ⅱb-Ⅲa antagonists[J].Br J Clin Pharmacol,2011,72:672-682.
[15]	Eikelboom JW,Hirsh J,Spencer FA,et al.Antiplatelet drugs:Antithrombotic Therapy and Prevention of Thrombosis,9th ed:American College of Chest Physicians Evidence-Based Clinical Practice Guidelines[J].Chest,2012,141:e89S-e119S.
[16]	Reddy S,Mathew M,Patel N,et al.Analyzing the Efficacy and Cost-effectiveness of Anti-platelet Therapy in Unstable Angina/Non-ST Elevation Myocardial Infarction:A Decision Analysis[J].Cureus,2019,11:e5321.
[17]	Gardiner EE,Andrews RK.Platelet Receptor Expression and Shedding:Glycoprotein Ⅰb-Ⅸ-Ⅴ and Glycoprotein Ⅵ[J].Transfus Med Rev,2014,28:56-60.
[18]	Ungerer M,Rosport K,Bültmann A,et al.Novel Antiplatelet Drug Revacept (Dimeric Glycoprotein Ⅵ-Fc) Specifically and Efficiently Inhibited Collagen-Induced Platelet Aggregation Without Affecting General Hemostasis in Humans[J].Circulation,2011,123:1891-1899.
[19]	Schupke S,Hein-Rothweiler R,Mayer K,et al.Revacept,a Novel Inhibitor of Platelet Adhesion,in Patients Undergoing Elective PCI-Design and Rationale of the Randomized ISAR-PLASTER Trial[J].Thromb Haemost,2019,119:1539-1545.
[20]	Firbas C,Siller-Matula JM,Jilma B.Targeting von Willebrand factor and platelet glycoprotein Ib receptor[J].Expert Rev Cardiovasc Ther,2010,8:1689-1701.
[21]	Li T,Fan M,Hou S,et al.A novel snake venom-derived GPIb antagonist,anfibatide,protects mice from acute experimental ischaemic stroke and reperfusion injury[J].Br J Pharmacol,2015,172:3904-3916.
[22]	Gong P,Li R,Jia H,et al.Anfibatide Preserves Blood-Brain Barrier Integrity by Inhibiting TLR4/RhoA/ROCK Pathway After Cerebral Ischemia/Reperfusion Injury in Rat[J].J Mol Neurosci,2019 Sep 3.doi:10.1007/s12031-019-01402-z.[Epub ahead of print].
[23]	Cho JR,Rollini F,Franchi F,et al.Unmet needs in the management of acute myocardial infarction:role of novel protease-activated receptor-1 antagonist vorapaxar[J].Vasc Health Risk Manag,2014,10:177-188.
[24]	Farag M,Patel H,Gorog DA.Adjunctive therapies to reduce thrombotic events in patients with a history of myocardial infarction:role of vorapaxar[J].Drug Des Devel Ther,2015,9:3801-3809.
[25]	Bliden K,Chaudhary R,Kuliopulos A,et al.Effects of vorapaxar on clot characteristics,coagulation,inflammation,and platelet and endothelial function in patients treated with mono-and dual-antiplatelet therapy[J].J Thromb Haemost,2019 Aug 24.doi:10.1111/jth.14616.[Epub ahead of print].
[26]	Patelis N,Kakavia K,Maltezos K,et al.An Update on Novel Antiplatelets in Vascular Patients[J].Curr Pharm Des,2018,24:4558-4563.
[27]	Smyth EM.Thromboxane and the thromboxane receptor in cardiovascular disease[J].Clin Lipidol,2010,5:209-219.
[28]	Cong Y,Wang L,Peng R,et al.Timosaponin AⅢ induces antiplatelet and antithrombotic activity via Gq-mediated signaling by the thromboxane A2 receptor[J].Sci Rep,2016,6:38757.
[29]	Viles-Gonzalez JF,Fuster V,Corti R,et al.Atherosclerosis regression and TP receptor inhibition:effect of S18886 on plaque size and composition--a magnetic resonance imaging study[J].Eur Heart J,2005,26:1557-1561.
[30]	Bots ML,Ford I,Lloyd SM,et al.Thromboxane prostaglandin receptor antagonist and carotid atherosclerosis progression in patients with cerebrovascular disease of ischemic origin:a randomized controlled trial[J].Stroke,2014,45:2348-2353.
[31]	Suzuki-Inoue K,Fuller GL,García A,et al.A novel Syk-dependent mechanism of platelet activation by the C-type lectin receptor CLEC-2[J].Blood,2006,107:542-549.
[32]	Estevez B,Du X.New Concepts and Mechanisms of Platelet Activation Signaling[J].Physiology (Bethesda),2017,32:162-177.
[33]	Qiao J,Al-Tamimi M,Baker RI,et al.The platelet Fc receptor,FcγRⅡa[J].Immunol Rev,2015,268:241-252.